Rifapentine is an FDA-approved drug for treating tuberculosis that forms part of a regimen for TB infection. Despite clear efficacy, rifapentine's utilization by US TB programs has been lower than expected. The Treatment Action Group and the Consortium to Respond Effectively to the AIDS/TB Epidemic partnered with the National Tuberculosis Controllers Association to conduct a survey among program managers to investigate barriers to rifapentine use in order to inform ongoing advocacy efforts to increase rifapentine access. Results of the survey were recently presented as a poster at the 18th Annual Conference of the Union North America Region annual meeting.
View the poster here.